SCM
ENTA icon

Stevens Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Stevens Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-12,514
Closed -$368K – 957
2016
Q1 		$368K Buy
+12,514
New +$348K 0.01% 636

Other funds holding ENTA

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return

Stevens Capital Management's ENTA Position: Q2 2016 in Review

Stevens Capital Management sold out of Enanta Pharmaceuticals (ENTA) in Q2 2016, closing a stake of 12,514 shares — an estimated $368K sold.

Stevens Capital Management first reported a position in ENTA in Q1 2016 and held it in 1 quarter. The position peaked at $368K in Q1 2016. 129 funds tracked by Wall St. Rank hold ENTA as of Q2 2016.

  • Stevens Capital Management reported no remaining Enanta Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • Stevens Capital Management sold 12,514 Enanta Pharmaceuticals shares in Q2 2016, an estimated $368K.
  • Stevens Capital Management first reported a position in Enanta Pharmaceuticals in Q1 2016 and held it in 1 quarter.
  • Stevens Capital Management's Enanta Pharmaceuticals position peaked at $368K in Q1 2016.
  • 129 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2016.

Based on Stevens Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.